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1. Introduction  
In spite of significant progress in recent years towards the development of new targeted 
therapies Cancer is still a largely unmet medical need and the leading cause of death in 
industrialized countries (Globocan Project, 2008). Cancer is continuously increasing and is 
associated with a variety of factors, including genetic predisposition, infectious agents, 
exposure to mutagens, as well as lifestyle factors (Minamoto et al, 1999). Cancer is linked to 
the occurrence of genetic and epigenetic changes (Heng et al, 2010) and indeed tumour cells 
harbor hundreds of these modifications as also witnessed by the recent results of genome 
wide analyses of cancer genomes (Sastre, 2011). This feature of cancer cells implies that they 
can be recognized as foreign entities and eliminated by our immune system, and is at the 
basis of the theory of immunosurveillance (Dunn et al, 2004).  
Several studies have shown that it is possible to establish clear correlates between the 
nature, density and location of immune cells within distinct tumour regions and the risk of 
disease relapse (reviewed in Mleknic et al, 2011). Compelling data have recently led to 
propose that an immune classification of patients, based on the density and the immune 
location within the tumour may have a prognostic value even superior to the standard TNM 
classification (Bindea et al, 2011; Fridman et al, 2011). In recent years a better knowledge of 
the immune system has led to an evolution of the initial concept of immunosurveillance into 
a more articulated theory of immunoediting (Schreiber et al, 2011). Cancer immunoediting 
acts as an intrinsic tumour suppressor mechanism that engages after cellular transformation 
has occurred and intrinsic tumour suppressor mechanisms have failed. One can envisage 
the existence of three sequential steps during clinical tumour evolution: elimination, 
equilibrium, and escape. In the first step, innate and adaptive immunity are capable of 
destroying transformed cells before they give rise to tumour masses. If this process is 
maximally efficient, then the host remains tumour free. If, however, cancer cell variants are 
not destroyed, they can enter into an equilibrium phase, in which their outgrowth is held in 
check by immunological mechanisms, which are principally due to the activation of IL-
12/IFN-dependent adaptive immunity, mainly driven by antigen-specific CD8+ and CD4+ 
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T cells. Equilibrium may still represent the end stage of the process and may restrain 
outgrowth of occult cancers for the lifetime of the host. However, as a consequence of 
constant immune selection pressure placed by the host on genetically/epigenetically 
unstable tumour cells, cancerous cells that are no longer recognized by adaptive immunity 
may emerge, become insensitive to immune effectors mechanisms and in addition they can 
induce the creation of an immunosuppressive environment. When tumour cells enter the 
escape phase in which their growth is no longer blocked by immunity, equilibrium is lost 
and disease becomes apparent. Re-establishing this equilibrium is the realistic goal of cancer 
immunotherapy. 
In spite of being the object of intensive efforts over the past decades, Cancer 
Immunotherapy has seen many more clinical failures than successes. However, very 
recently major breakthroughs have been achieved, and these have led us to believe that this 
approach may become an established platform for the therapy of cancer within the next 
decade. One can envisage three distinct avenues for Cancer immunotherapy: a) Adoptive 
Cell Therapy (ACT); b) systemic immune-modulators; c) therapeutic cancer vaccines. ACT is 
based upon the possibility to isolate, in vitro expand and re-inject in immunodepleted hosts, 
tumour-specific T cells. This approach has seen its best demonstration in the treatment of 
patients with advanced metastatic melanoma. Superb clinical results have been obtained 
with objective response rates of up to 49-72% and disease control in some cases lasting 
several years (Rosenberg and Dudley, 2009). Although evolution of this approach such as 
genetic modification of T cells to redirect their effector cell specificity may open up to 
broader applications (Morgan et al, 2010), this strategy has several limitations that currently 
limit its wide applicability: it is patient specific, very expensive, requires hospitalization and 
can only be executed in highly specialized clinical centers. In contrast, systemic 
immunomodulators such as monoclonal antibodies against CTLA-4 or PD-1/PD-L1, do not 
suffer the manufacturing and delivery problems shown by ACT. On March 2011, FDA 
approved Ipilimumab (Yervoy® - BMS) (Culver et al, 2011), a human monoclonal antibody 
against CTLA-4 for the treatment of metastatic melanoma, based on the results of a 
randomized, controlled Phase III, where Ipilimumab showed statistically increased overall 
survival compared with controls (Hodi et al, 2010). Although the clinical development of 
anti PD-1 antibodies is at an earlier stage as compared to anti CTLA-4, results are highly 
promising both for efficacy and tolerability (Kline and Gajewski, 2010). Finally cancer 
vaccines recently gained increased visibility due to the demonstration that Sipuleucel-T, a 
immune cell vaccine for the treatment of hormone refractory prostate cancer, is capable of 
increasing overall survival of cancer patients (Kantoff et al, 2010). These results led to FDA 
approval as Provenge® (Dendreon) in year 2010 (Cheever and Higano, 2011). This recent 
approval has acted as a strong injection of enthusiasm in an area that has long suffered 
major setbacks.  
In this review we will focus mainly on recent developments for therapeutic cancer vaccines 
and will not discuss in detail ACT and systemic immunomodulators (Klebanoff et al, 2011). 
Major emphasis will be given to aspects that are critical to increase vaccine immunogenicity 
and probability of success in the clinic. We believe these are mainly: a) efficient vaccine 
delivery systems, b) development of response biomarkers, c) modified clinical endpoints and 
d) combinatorial treatments with chemotherapy or other agents. In analyzing vaccine delivery 
systems a greater attention will be given to genetic vaccines which we believe represent the 
most promising methods to elicit immune responses against a wide variety of tumour antigens 
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especially when administered in combined immunization protocols (heterologous 
prime/boost). We invite the reader to other recent excellent reviews for aspects of tumour 
immunology and cancer immunotherapy that we may have missed in our work (Steer et al, 
2010; Klebanoff et al, 2011; Palucka et al, 2011; Vergati et al, 2010; Aldrich et al, 2010) . 
2. Tumour immunology  
Our immune system has the intrinsic capability of recognizing tumour cells as foreign 
entities and to mount responses capable of impacting upon disease evolution. In this section 
of the chapter we review the main evidences for this spontaneous response, what are the 
targets of this response, which are the principal components of the immune system involved 
and what is curtailing this response leading to tumour escape and lack of control of the 
immune system over cancer. 
2.1 Immunosurveillance and Immunoediting  
The key studies that unequivocally demonstrated the role of the immune system in the 
control of cancer development date back to about a decade ago when mouse models of 
immunodeficiency on pure genetic backgrounds became available. These studies showed 
that interferon– (IFN-) is a key factor responsible for the immunological rejection of 
transplanted tumour cells (Dighe et al, 1994). Furthermore, mice lacking IFN- response 
(either as a consequence of IFN- receptor or STAT1 inactivating mutations) or adaptive 
immunity as a whole (RAG2 -/- deficient mice) are more susceptible to carcinogen induced 
or spontaneous tumours (Kaplan et al, 1998; Shankaran et al, 2001, Street et al, 2002). These 
evidences collectively demonstrated that the immune system can function as an extrinsic 
tumour suppressor. However, as mentioned in the introduction section, a new emerging 
concept in cancer immunology is that the immune system is not simply a component that 
protects the host against tumour development, but rather an agent that shapes tumour 
quality. In other words, tumours that develop in an immunocompetent organism are the 
resultant of a selection process imposed by the host and by the type of immune response 
that the host immune system is capable to mount. This concept was originated by pivotal 
studies that demonstrated that tumours developing in immunocompetent mice have a 
different molecular profile, are less immunogenic than tumours developing in 
immunodeficient hosts and progress more rapidly when implanted into naïve wt recipient 
mice (Dunn  et al 2002). 
Although both natural and acquired immunity are required to fully exert this control 
mechanism, the principal contribution comes from adaptive immunity and in particular 
from the development of tumour-antigen-specific T cells, mainly CD8+, but also CD4+. 
Indeed the fundamental principle of cancer immunology is that tumour cells express 
antigens (TAAs – tumour associated antigens) that differentiate them from normal cells. The 
existence of tumour antigens has been abundantly demonstrated both in mouse and human 
studies (Novellino et al, 2005). In the case of human cancers, identification of tumour 
antigens was made possible via the development of methods that used as probes antibodies 
and CD8+ T cells derived from patients and capable of reacting with the autologous tumours 
(Sahin et al, 1997; Coulie et al, 1997). In the next section we will describe in more detail the 
types and nature of TAAs under study. 
What is happening in the tumour cells that makes them “invisible” or “poorly visible” to the 
immune system? Certainly the most common mechanism is believed to be loss of tumour 
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antigen expression, which can occur in at least three possible ways: a) downmodulation of 
tumour antigen gene expression consequent mainly to epigenetic changes; b) 
downregulation of MHC class I protein expression and antigen presentation to the cell 
surface; c) alterations in tumour cells of the machinery responsible for antigen processing 
and peptide loading onto MHC molecules. In addition to this, it has to be taken into account 
that tumour cells develop mechanisms of resistance to apoptosis and to the cytotoxic effects 
of immunity through, for instance, upregulation of anti-apoptotic BCL-2 proteins or 
activation of transcription factors such as STAT-3. All these processes are strongly favoured 
by the genetic/epigenetic instability intrinsic of tumour cells, which in the presence of a 
continuous selection favors the emergence of “immune stealth” clones. 
If we analyze in detail the three phases of immunosurveillance/immunoediting, namely 
Elimination, Equilibrium and Escape, the phase where we have more direct proof of the 
activity of the immune system is the Equilibrium phase. This phase can represent a type of 
tumour dormancy where growth of tumour cells is kept at bay for a long period of time, even 
for the entire life of an organism. Strong evidence for this phenomenon first came when 
immunocompetent mice treated with low dose carcinogens such as methylcolantrene, were 
shown to harbor occult cancers for an extended period of time (Koebel et al, 2007). 
Intriguingly, when these mice were subjected to treatments that selectively affected adaptive 
immunity, but not innate immunity, tumours rapidly developed, thus demonstrating that 
equilibrium is established only when a Tumour Antigen Specific CD8+ and CD4+ response has 
occurred. This may explain the clinical findings of aggressive tumour arising in organs from a 
donor apparently cured from cancer, when transplanted into a patient (MacKie et al, 2003). 
Although studies of tumour development in mice served as the main driver for the 
formulation of the cancer immunosurveillance/immunoediting hypothesis, strong 
demonstration has also been obtained in humans by three different types of evidence. As 
mentioned before, the first is the demonstration that cancer patients develop detectable 
levels of antibodies and T cell responses to tumour antigens (Dougan and Dranoff, 2009). 
The second one is that patients affected by immunodeficiencies are at higher risk of 
developing cancers (Dunn et al, 2002). The third and strongest one is that intratumoural 
infiltration by cells of the immune system correlates with disease evolution. In this respect 
several studies have shown that the quantity, quality, and spatial distribution of tumour 
infiltrating lymphocytes correlate with patients survival. In fact, tumour infiltration by IFN-
 producing CD8+ and CD4+ T cells has been associated with an improved prognosis for 
patients with several different cancer types, including melanoma (Clemente et al, 1996; van 
Houdt, 1998), colorectal cancer (Chiba et al, 2004) and ovarian cancer (Nelson, 2008). More 
recent studies in colorectal cancer have extended these findings and have shown, through a 
global analysis of the tumour microenvironment from both a morphological standpoint and 
from a system biology approach, that the nature, functional orientation, density and location 
of cells of the adaptive immune system within distinct tumour regions influence the risk of 
relapse (Mlecnik et al, 2011). The same authors have come to the conclusion that the density 
and the immune cell location within the tumour may have a prognostic value superior to the 
standard TNM classification, and that tumour spread is statistically dependent upon the 
extent of the host-immune reaction (Bindea et al, 2011).  
2.2 Tumour associated antigens (TAAs) 
In the past years, several TAAs have been identified having unique expression patterns or 
being overexpressed by cancer cells. These antigens, under appropriate conditions, can be 
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recognized by components of the immune system (Campi et al, 2003; Frenoy et al, 1987; 
Kawashima et al, 1998). Therefore, many current vaccination strategies are designed to 
induce antibody as well as cell-mediated immune responses against the antigen of interest. 
A high number of TAAs has been discovered and evaluated in pre-clinical and clinical 
studies with different results. A list of well-known TAAs subdivided in four main categories 
is provided in Table 1. Among the most studied and validated TAAs, vaccinations against 
CEA (Marshall et al, 2003), HER-2/neu (Shumway et al, 2009), TERT (Vonderheide, 2008), 
EpCAM (Chaudry et al., 2007), survivin (Andersen and Thor, 2002), prostate-specific 
antigens (Doehn et al., 2008) provided good immunologic results. In light of the increasing 
interest and potential for cancer immunotherapy, the National Cancer Institute recently 
conducted an interesting pilot project to prioritize cancer antigens and to develop a priority-
ranked list of cancer vaccine target antigens based on predefined and pre-weighted objective 
criteria (Cheever et al., 2009). Shared TAAs 
Among the shared TAAs, the following three main groups can be identified: (1) cancer-testis 
(CT) antigens, (2) differentiation antigens, and (3) widely occurring overexpressed antigens.  
Among shared tumour-specific antigens, cancer-testis (CT) antigens are expressed in 
histologically different human tumours and, among normal tissues, in 
spermatocytes/spermatogonia of the testis and occasionally in placenta. CT antigens result 
from the reactivation of genes which are normally silent in adult tissues but are 
transcriptionally activated in different tumour histotypes (De Smet et al., 1999). Many CT 
antigens have been identified and used in clinical trials, although little is known about their 
specific functions, especially with regard to malignant transformation. This group of TAAs 
includes MAGE-A1 (Chaux et al., 1999) and NY-ESO-1 (Jager et al., 1998). Differentiation 
antigens are shared between tumours and the normal tissue of origin and found mostly in 
melanomas and normal melanocytes (Gp100, Melan-A/Mart-1, and Tyrosinase), although 
they are also found in epithelial tissues and tumours such as prostate tumours (prostate-
specific antigen [PSA]). To variable extent, normal tissues can be target of the elicited 
immunity against shared TAAs. An example is the vitiligo developing as a consequence of 
the immune response in melanoma patients undergoing immunotherapy. Vaccine-induced 
T cells recognizing gp100 and tyrosinase are present at the vitiligo lesions and normal 
melanocytes are eliminated by the immune system (Jacobs et al., 2009). Importantly, this 
effect has been associated to a clinical response. Additionally, expression of several oncofetal 
antigens appears to be increased in many adult cancer tissues, including carcinoembryonic 
antigen (CEA), which is highly expressed in colon cancer (Tsang et al., 1995). 
TAAs from this group, despite representing self-antigens, have been and still are commonly 
used in current cancer vaccination trials, often together with CT antigens. Widely occurring, 
overexpressed TAAs have been detected in different types of tumours as well as in many 
normal tissues, and their overexpression in tumour cells can reach the threshold for T cell 
recognition, breaking the immunological tolerance and triggering an anticancer response. 
Among the most interesting TAAs of this group are the antiapoptotic proteins (survivin) 
(Schmidt et al., 2003), hTERT (Vonderheide et al., 2008), and tumour suppressor proteins 
(e.g., p53) (Umano et al, 2001). 
Unique tumour antigens. Unique TAAs are products of random somatic point mutations 
induced by physical or chemical carcinogens and therefore expressed uniquely by 
individual tumours and not by any normal tissue, representing the only true tumour-
specific antigens (Ags) (reviewed in Parmiani et al., 2007). Such Ags characterize each single 
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neoplasm and were shown to be diverse between tumours induced in the same animal or 
even in different tissue fragments from the same tumour nodule. A relevant feature of 
unique Ags is their potential resistance to immunoselection if the mutated protein is crucial 
to the oncogenic process and thus indispensable for maintaining the neoplastic state. As a 
consequence, unique Ags should elicit an immune response clinically more effective than 
that of shared Ags. However, identification of unique tumour antigens for solid human 
tumours requires sequencing of the whole genome of each individual tumour in order to 
identify mutated genes and select peptides whose motifs are predicted to be presented by 
the patient's HLA alleles. Moreover, each tumour bears highly heterogeneous sets of defects 
in different genes which need to be further verified for their substantial contribution to the 
tumour development and progression and, consequently, for their relevance as vaccine 
targets (Fox et al., 2009). An interesting class of potential TAAs is associated with fusions 
between different proteins. Best example is the Bcr–Abl fusion protein,  the driving force in 
chronic myelogenous leukemia (CML) (Daley et al., 1990). By establishing a causal link 
between a specific chromosomal lesion and a specific malignancy, BCR–ABL also pioneered 
cancer therapy: the TK inhibitor, imatinib (Gleevec), was introduced as the first widely used 
targeted therapeutic (Druker et al., 2001). Similar discoveries led to the characterization of 
causative fusions in other hematological malignancies. A variety of prostate cancer gene 
fusions have been identified so far (reviewed in Shah and Chinnaiyan, 2009), characterized 
by 5'-genomic regulatory elements, most notably the androgen-controlled prostate specific 
gene, transmembrane protease serine 2 (TMPRSS2), fused to members of the 
erythroblastosis virus E26 transforming sequence family of transcription factors, most 
notably ERG, leading to the overexpression of oncogenic transcription factors. This class of 
potential TAAs is matter of extensive studies and holds promise for personalized vaccine 
applications. 
Viral Antigens. Some viruses, such as human papillomavirus (HPV) and hepatitis B virus 
(HBV) can induce cancer. As a matter of fact, HBV vaccination in newborns has eradicated 
hepatocellular carcinoma (HCC) in populations at high risk (McMahon et al, 2011; Blumberg et 
al., 2010). The high-risk HPV types (e.g., HPV16) are causally related to the development of 
anogenital lesions, including vulvar intraepithelial neoplasia (VIN), and their subsequent 
progression to invasive squamous cell carcinoma. The expression of viral antigens (hence non-
self proteins) such as HPV E6 and E7 proteins by cancer cells can represent the mechanism 
through which the tumour becomes visible to the immune system. Recently, promising results 
have been obtained by vaccination of patients with HPV16 E6/E7 synthetic long-peptide 
vaccine (Van der Burg and Melief, 2011), providing an important proof of concept for the 
development of therapeutic cancer vaccines against cervical and anal cancers.  
Stromal Antigens. During transformation, reciprocal interactions occur between neoplastic 
and adjacent normal cells, i.e. fibroblasts, endothelial, and immunocompetent cells. In general, 
stroma cells contribute 20–50% to the tumour mass, but the stromal compartment may account 
for up to 90% in several carcinomas. In contrast to cancer cells, tumour stroma cells are 
genetically more stable so that at least some immune evasion mechanisms of tumours do not 
apply to these cells. Nevertheless, stroma cells differ from their normal counterparts by 
upregulation or induction of various antigens (reviewed in Hofmeister et al., 2006). Some of 
the tumour stroma-associated antigens (TSAAs) are highly selective for the tumour 
microenvironment. TSAAs are also expressed by a broad spectrum of solid tumours, thus 
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therapies designed to target tumour stroma are not restricted to a selected tumour type. 
Cancer-associated fibroblasts (CAFs) are reactive fibroblasts with a phenotype differing from 
that of quiescent fibroblasts in normal adult tissue. CAFs contribute to the development of 
cancer by secreting growth promoting factors such as TGF-, matrix degrading enzymes, and 
angiogenic factors, e.g. MMPs or vascular endothelial growth factor (VEGF). Endothelial cells 
have a major part in tumour progression since they are necessary for angiogenesis. Tumour 
endothelial cells (TECs) express surface receptors and secrete factors that sustain their own 
growth by an autocrine pathway. Another target cell population for immune intervention 
present in the tumour microenvironment are tumour-associated macrophages (TAMs, see also 
paragraph 2.3). Among the proteins explored as promising stromal immunotherapy targets it 
is worth mentioning Fibroblast Activation Protein a (FAP, seprase), a surface glycoprotein 
selectively expressed in reactive stromal fibroblasts of solid tumours,  Carbonic Anhydrase IX 
(CAIX) an important pH regulator, Matrix Metalloproteases (MMP) such as MMP11 (Peruzzi 
et al., 2009), extracellular angiogenic factors, such as Vascular Endothelial Growth factor 
(VEGF) and its receptor VEGFR2 and basic Fibroblast Growth Factor (bFGF). Tumour 
endothelial markers (TEMs), among them TEM1 and TEM8, are overexpressed during tumour 
angiogenesis and prostate-specific membrane antigen (PSMA) is another endothelial cell 
surface molecule of particular interest for vascular targeting. In conclusion, ideal target stromal 
proteins are those selectively induced or upregulated in the tumour micromilieu, and confer a 
growth or survival advantage to the tumour.  
 
Shared Antigens Features Type of Tumour Examples
Cancer Testis (CT) 
Ags
Expressed only by
tumours and testis
Melanoma, 
lymphoma, bladder, 
breast, colon, lung
BAGE, GAGE,
MAGE, NY-ESO-1
Differentiation Ags Expressed also by
normal cells
Melanoma,prostate, 
colon, breast
Gp100, MART-1, 
tyrosinase, CEA, PSA
Overexpressed Ags Expressed by tumor
cells prevalently
Liver, colon, breast,
ovary, bladder, 
prostate, esophagus, 
lymphoma
p53, Her2/neu, 
survivin, hTERT
Unique Antigens Features Type of Tumour Examples
Unique Expressed by a single 
tumor
Melanoma, NSCLC, 
RCC
CDǂ-actin-m, K-4/m, 
-actin-m, Myosin-m
Viral Antigens Features Type of Tumour Examples
Viral Encoded by genome 
of oncogenic viruses 
HCC, anogenital
lesions
HBV, HPV E6 and E7
Stromal Antigens Features Type of Tumour Examples
Fibroblast TSAA Expressed by CAFs Ubiquitous FAPa, CAIX, MMP11
Endothelial TSAA Expressed by TECs Ubiquitous VEGF, VEGFR2, 
TEMs, PSMA  
Table 1. Classification and examples of TAAs and TSAAs. 

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2.3 Immune suppression mechanisms  
A strong and persistent immune response against cancer is necessary but not sufficient to 
controlling tumour growth in the escape phase. For example, while robust T cell responses 
generated by vaccinations against HPV are capable of successfully controlling pre-
malignant intraepithelial neoplasias (Welters et al, 2010),  in clinical trials of tumour 
vaccines against large, invasive malignancies the effective generation of tumour antigen-
specific T cells is not predictive of clinical efficacy (Radoja et al, 2001). Although this 
discrepancy may be due in part to differences in the affinity/avidity of effector T cells 
developing against self vs exogenous antigens, the principal cause is believed to be the 
establishment of an immunosuppressive state within the tumour microenvironment 
(reviewed by Gajewski et al, 2006). This immunosuppression is not due to a single 
mechanism but to the concerted action of several processes. In first instance the presence of 
regulatory T cells (Tregs) and Myeloid-derived suppressor cells (MDSCs), which play a 
direct inhibitory role on host-protective antitumour responses.  
Tregs are CD4+ T cells which constitutively express CD25 and the transcription factor FoxP3 
(Nishikawa and Sakaguchi, 2010). It is unclear what proportion of intratumoural Tregs react 
with specific tumour antigens (Wang et al, 2005), or instead are recruited through the 
recognition of shared self-antigens co-expressed by tumour cells (Darrasse-Jeze et al, 2009). 
At any rate, their inhibitory function is exerted via the production of immunosuppressive 
cytokines such as IL-10 and TGF, the expression of negative co-stimulatory receptors such 
as CTLA-4 and PD-1, and the expression of IDO. IDO (indoleamine 2,3-dioxygenase) is an 
enzyme responsible for a rate-limiting step in tryptophan catabolism and is strongly 
induced in the tumour environment by IFN-. The immunosuppressive effect of IDO 
expression is due both to reduction of local levels of tryptophan and to the generation of 
cytotoxic catabolites kynurenins, which affect T cell activity and dendritic cell survival 
(Soliman et al, 2010). Several studies have shown that in several cancer types the presence of 
regulatory CD4+CD25+ T cells in tumours inversely correlates with disease outcome (Woo et 
al, 2001; Curiel et al, 2004)  
MDSCs or Tumour Associated Macrophages (TAMs) are a heterogenous group of myeloid 
progenitor cells and immature myeloid cells that inhibit lymphocyte function  by inducing 
Tregs, producing TGF, depleting essential aminoacids as tryptophan, arginine and 
cysteine, and inducing down-regulation of L selectin on T cells (Ostrand-Rosenberg, 2010; 
Lindenberg et al, 2011). T cells must have an L-selectin phenotype to home to lymphnodes 
and inflammatory sites where they encounter antigens and are activated. TAMs therefore, 
perturb T cell trafficking and inhibit T cell activation. Furthermore, immunosuppression 
appears to be enhanced by active angiogenesis and angiogenic cytokines like VEGF 
(Johnson et al, 2007), also through a possible direct effect on dendritic cells.  
Recent studies have shown that a symbiotic relationship exists between tumour cells and 
TAMs, in which tumour cells attract TAMs and sustain their survival, with TAMs 
responding to microenvironmental factors in tumours such as hypoxia by producing 
important mitogens, growth factors and enzymes that stimulate tumour growth 
angiogenesis (Bingle et al, 2002). Actually it seems that in response to different stimuli, 
TAMs differentiate into subsets capable of stimulating different pro-tumourigenic functions. 
For example in areas of invasion TAMs promote cancer cell motility, in perivascular areas 
they promote metastasis, and in avascular and perinecrotic areas hypoxic TAMs stimulate 
angiogenesis (Lewis and Pollard, 2006). Finally in a very recent study it has been shown that 
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macrophage infiltration in tumours is able to affect chemotherapy (De Nardo et al, 2011). 
Indeed these authors have shown that TAM depletion in highly infiltrated tumours 
increased the antitumour efficacy of paclitaxel, and this was at least in part due to their 
suppression of the antitumour functions of cytotoxic T cells. This study therefore confirms 
the high complexity of the immune cell interactions in tumours (DeNardo et al, 2010) and 
shows that cross-talk between TAMs and cytotoxic T cells impairs effective tumour 
eradication by immune mechanisms. 
Unraveling the mechanisms at the basis of immunosuppression in the tumour 
microenvironment has led to the definition of novel targets for therapeutic intervention. 
Agents directed against these new targets, such as for example IDO or PD-1, may act in 
concert with cancer vaccines to enhance their efficacy, in particular in conditions of 
advanced tumour development. We believe that the clinical efficacy of anti CTLA-4 
antibody Ipilimumab is in part linked to the inhibition of immunosuppressive processes. 
Indeed recent studies have demonstrated that maximal anti-tumour effects of CTLA-4 
blockade are due to the concomitant blockade not only of effector T cells, but also of Tregs 
(Peggs et al, 2009). Also, it cannot be excluded that at least in part the clinical efficacy of the 
anti-VEGF antibody Bevacizumab is due to inhibition of the immunosuppressive function of 
VEGF (Chouaib et al, 2010). 
3. Types of cancer vaccines 
Different technologies have been employed to develop cancer immunotherapies. These 
include passive immunotherapy, based on the adoptive transfer of ex-vivo activated immune 
cells, immunomodulators (including cytokines) or tumour specific antibodies; and active 
immunotherapy, aimed at activating the patient’s own immune system via the 
administration of a therapeutic vaccine. To date, active cancer immunotherapy trials have 
included therapeutic vaccination with recombinant viral vectors encoding TAAs, 
recombinant proteins with appropriate adjuvants, antigen-loaded Dendritic Cells (DCs), 
DNA encoding tumour-associated antigens, heat shock proteins and synthetic peptides (see 
next paragraphs). However, apart from melanoma, in which impressive clinical responses 
have been observed in a small proportion of patients,  the recent success of Sipuleucel-T (see 
paragraph 3.1.2.1) and the promise of PROSTVAC-VF (see paragraph 3.2.1), most results 
have been disappointing. Therefore, the continuous development of novel vaccine strategies 
and technologies is needed to improve recognition, immune response, effector functions, 
and trafficking of T cells induced by vaccination. These goals may be achieved by the 
concurrent administration of novel immunotherapeutics with an immunopotentiating 
profile (see section 4.3).  
3.1 Cell-based vaccines  
A first category of cancer vaccines under evaluation is based on delivery of cells. As pointed 
out before, we will not discuss in this chapter ACT but only Whole Tumour Cell Vaccines 
and Dendritic Cells vaccines. 
3.1.1 Whole cell vaccines 
Autologous tumour cells are an obvious source of TAAs for vaccination purposes, since, by 
definition, all relevant candidate TAAs should be contained within them. In early clinical 
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trials, individualized tailor-made vaccines prepared from whole tumour cells were 
associated with limited activity, presumably due to the already biased nature of the host 
immune response to specific TAAs (Vermorken et al. 1999; Jocham et al., 2004). However, 
due to the mechanism of immunologic tolerance, this approach has resulted in poor 
immunogenicity and different categories of adjuvants have been evaluated in the past years 
(de Gruijl et al., 2008). 
Perhaps the most explored approach in the clinic is GVAX (Cell Genesys). Autologous 
tumour cells, transduced with GM-CSF were shown to induce tumour-specific immunity 
and durable anti-tumour responses in a number of trials. The efficacy of GVAX depends on 
the cross-presentation of vaccine-derived TAAs to specific cytotoxic T lymphocytes (CTLs) 
in vivo (Hege et al., 2006). This process of cross-priming is facilitated by the activation of 
Dendritic Cells (DC), by GM-CSF. This finding led to the realization that allogeneic cells 
would also present a viable source of TAAs, which would be taken up by DCs and then 
presented in the context of appropriate MHC alleles to autologous CTLs. Advantages of the 
use of allogeneic cells are obvious: (1) through the use of antigenically well-defined cell lines 
one has access to a sustained and virtually limitless source of material, (2) the use of cell 
lines allows for a highly standardized and large-scale production of vaccine, (3) the use of a 
single batch of allo-vaccines for all vaccinees, independent of HLA haplotype, eliminates 
variability in the quality and composition of the vaccines and facilitates reliable comparative 
analysis of clinical outcome. Eliminating the need for the continuous production of tailor-
made individual vaccines simplifies the logistics, reduces the laboriousness of vaccine 
production and distribution, and increases its cost-effectiveness.  
3.1.2 Dendritic cell vaccines 
Dendritic Cells (DCs) collect antigens from various tissues and carry them to secondary 
lymphoid organs to ultimately activate antigen-specific T cells. Myeloid DCs and 
plasmacytoid DCs are the 2 main subsets of DCs (Palucka et al, 2011. Through toll-like 
receptors (TLRs) 7 and 9, plasmacytoid DCs recognize viral nucleic acids and secrete type I 
interferon (IFN). Three myeloid DC subsets localize to the skin. Langerhans cells (LCs) are 
found in the epidermis, while CD1+DCs and CD14+DCs are found in the dermis. 
CD14+DCs produce interleukin (IL)-1ǃ, IL-6, IL-8, IL-10, IL-12, GM-CSF, membrane cofactor 
protein-1, and tumour growth factor-ǃ. LCs produce IL-15, which is a growth and 
maintenance factor for CD8+ T cells and natural killer cells. LCs are more efficient in cross 
presentation and prime higher avidity T cells with reported greater capacity for cell kill. 
Although DC biology is complicated, it is clear that these cells are the critical regulators of 
adaptive T-cell and B-cell responses. These findings have provided the rationale for ex vivo 
antigen loading of DCs for the preparation of vaccines. DCs have been loaded with tumour 
antigens in the form of peptides, proteins, tumour lysates, and mRNAs. Alternatively, they 
have been fused with tumour cells or infected with viral vectors encoding tumour-
associated antigens (reviewed in Le et al., 2010).  
Clinical development of DC-based cancer vaccines has several aspects that make this 
technology not ideal for application on a large scale. The first aspect is the difficulty to set 
up standardized procedures for the reliable production of functioning DCs. Currently, it is 
difficult to demonstrate that each preparation has the same levels of processed and 
presented antigen, and can induce an equivalent degree of immune response after 
administration. Quality control in the processing of cellular products is critical to the 
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integrity of the product. Large amounts of autologous peripheral blood mononuclear cells 
must be cultured in the presence of several cytokines making their off-the-shelf 
marketability challenging. There are critical issues not only in ensuring the proper 
maturation status of the DCs but also in the precise selection of appropriate subsets of DCs 
required to elicit the desired response. Other aspects include the significant costs of 
manufacturing the product and the huge amount of labor required to produce a viable 
product within a short time frame.  
3.1.2.1 The Sipuleucel-T (Provenge) experience 
Despite the above described technical hurdles, a immune cell-based vaccine, Sipuleucel-T, 
recently received Food and Drug Administration approval based on a successful phase III 
trial showing improvement in overall survival (OS) in men with asymptomatic or minimally 
symptomatic metastatic advanced castrate resistant prostate cancer (CRPC). The key to 
manufacturing feasibility of Sipuleucel-T is the absence of DC purification in the 
preparation. The preparation of a Sipuleucel-T product involves a leukapheresis to obtain 
the peripheral blood of the patient. The leukapheresed specimen is then transferred to the 
company manufacturing facility. The cell pellet containing DCs (CD54+), T lymphocytes 
(CD3+), B lymphocytes (CD19+), monocytes (CD14+), and natural killer cells (CD56+) is 
exposed to PA2024, an engineered antigen-cytokine fusion protein consisting of Prostate 
Acidic Protein (PAP) and GM-CSF. GM-CSF facilitates uptake of the fusion protein by DCs 
and promotes DC stimulation. PAP is the tumour antigen used in this vaccine. The final 
product is transported to the patient at 4°C and infused intravenously within 8 hours of 
formulation. Because the product is a mixture of cell types, the precise mechanism of action 
has not been established. It is not clear it is not clear if induction of anti-prostate cancer 
responses involves in vivo activation of T cells by the loaded DCs in the preparation. It is 
also possible that T cells in the preparation are activated by ex vivo manipulations and that 
this therapy actually represents an alternative form of adoptive T-cell therapy. The paucity 
of available immunologic data to date precludes mechanicistic dissection of this drug. 
Phase I and II trials of Sipuleucel-T demonstrated T-cell and antibody responses to the 
antigen (Burch et al., 2004). Immune responses correlated with improved time to 
progression (TTP). Two sequential phase III placebo-controlled studies were subsequently 
conducted in patients with metastatic CRPC, with a primary end point of TTP. Integrated 
data again suggested a survival benefit but failed to show significance for the 
predetermined clinical end point. In this combined data set, a total of 225 patients were 
randomized to Sipuleucel-T (n = 147) or placebo (n = 78). There was a 33% reduction in the 
risk of death (HR 1.50; 95% CI 1.10– 2.05; P = 0.011). There was only a 4.8% PSA response in 
the combined analysis. Median survival was 23.2 versus 18.9 months and the percentage 
alive at 36 months was 33% versus 15% in favor of the treatment groups. Cumulative CD54 
up-regulation, a measure of product potency, correlated with Overall Survival (OS). As a 
result of these studies, Dendreon pursued a new study, known as the IMmunotherapy for 
Prostate Adeno Carcinoma Treatment (IMPACT) trial. OS was the primary end point. Five 
hundred twelve patients were enrolled in this study. Despite absence of clinical response to 
Sipuleucel-T or effect on TTP, the study met its primary end point of survival benefit. 
Subjects in the treatment group experienced a statistically significant increase in median 
survival vs controls (25.8 vs. 21.7 months respectively) and greater OS at 36 months (31.7% 
vs. 23%). The final analysis after 349 events demonstrated a median OS benefit of 4.1 months 
(HR 0.759; 95%CI 0.606–0.951; P = 0.017) (www.dendreon.com). 
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3.1.3 Heat shock proteins-based vaccines 
Another interesting approach in cancer vaccine development is the use of heat shock protein 
(HSP)-peptide complexes, as natural host vector for vaccination (reviewed in di Pietro et al., 
2009). Heat shock proteins are intracellular molecules of a family characterized by members 
of similar molecular mass (such as hsp70 and hsp90) that act as chaperones for a repertoire 
of peptides, including normal self-peptides and antigenic peptides. During both protein 
synthesis and breakdown, heat shock protein complexes are released from cells still 
associated non-covalently with peptides. Release by necrotic cells function as endogenous 
danger signals as well as a method to cross-present antigens to DCs. In fact, DCs have a 
specific receptor for heat shock proteins (CD91) and its engagement leads to their 
maturation. HSPs complexed with antigenic peptides have been shown to efficiently deliver 
peptides into the MHC class I processing pathway thus generating cellular immune 
responses. This phenomenon has been demonstrated in mouse and human tumours. In the 
latter, hsp70-peptide complexes extracted from melanoma cells have been found to contain 
well-known peptides on the basis of their ability to stimulate antigen-specific CD8+ T cells 
from melanoma patients’ peripheral blood mononuclear cells (PBMCs). This observation has 
led to the purification of HSP-complexes from the tumours of patients and their 
administration as vaccines. The immunogenicity of tumour-derived HSP-peptide 
complexes, like the immunogenicity of experimentally induced tumours of mice and rats, 
has been shown to be individually tumour specific and not tumour type specific. These 
observations have led to the conclusion that the relevant tumour-antigenic, 
immunoprotective peptides are derived from unique rather than from shared tumour 
antigens.  
Heat shock proteins explored for clinical immunotherapy may contain a defined antigen (E7 
antigen derived from the human papilloma virus, MAGE tumour antigen, etc) or nondefined 
tumour antigens, which require the individualized production of heat shock proteins from 
fresh tumour samples. This could be a limitation, since several grams of tumour tissue must be 
available for the patient to be eligible for the trial. Following a number of trials 
(http://www.agenusbio.com/prophage/past-trials.html ) in a range of tumour types 
(pancreatic cancer, Kidney cancer, Non-Hodgkin’s lymphoma, CRC, gastric cancer) the 
tumour specific HSP-complexes vaccine named HSP peptide complex-96 (HSPPC-96 or 
Oncophage® or Prophage; Agenus, Lexington, MA, USA) has been approved in Russia as 
Oncophage® for the adjuvant treatment of kidney cancer patients at intermediate risk for 
disease recurrence. Currently Agenus is planning a registration Phase III trial for recurrent and 
newly diagnosed glioblastoma (http://www.agenusbio.com/prophage/ongoing-trials.html) 
in order to obtain drug approval by EMA. 
3.1.4 Peptide vaccines 
Peptide-based cancer vaccines represent the most popular approach to direct the immune 
system against malignant cells, since they are usually made of single epitopes, the minimal 
immunogenic region of an antigen. Peptides can be synthesized in a standardized manner 
and their cost of production is relatively low. Thus peptide vaccines have been the 
technology of choice by several group. Despite the strong rationale, the promising 
preclinical results and the frequent induction of antigen-specific immune responses in 
patients, peptide-based cancer vaccines have yielded relatively poor results in the clinical 
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setting and so far none of advanced clinical trials with peptide vaccines has resulted in 
statistically significant increase in survival. A particular mention deserve the results of the 
phase III clinical trial in 676 metastatic melanoma patients, which compared the efficacy of a 
gp100 peptide vaccine, with that of the fully human anti CTLA-4 antibody ipilimumab, or 
with the combined agents (Hodi et al, 2010). Ipilimumab when compared to gp100 alone 
improved median overall survival from 6.4 to 10.1 months (hazard ratio for death, 0.68; P < 
0.001). More importantly no difference in survival was detected between the Ipilimumab 
alone vs Ipilimumab plus vaccine groups (median overall survival 10.1 vs 10.0 months, 
hazard ration with ipilumumab plus gp100, 1.04; P = 0.76). Based on these results 
ipilimumab was recently approved by FDA for the treatment of unresectable stage III and 
IV melanoma, with the name of Yervoy® (BMS). A possible interpretation  for the lack of 
efficacy of a peptide vaccine in a patient population otherwise responsive to 
immunotherapy is the necessity to generate a polyclonal immune response directed 
simultaneously against several MHC class I epitopes. This could not be achieved in the 
Ipilimimab trial cited above because of the use of a single peptide. In order to overcome this 
limitation alternative approaches are being undertaken which make use of a combination of 
immunogenic peptides.  
Advances in the engineering of peptides and in our understanding of the molecular 
mechanisms underlying an effective immune response against tumours have renewed the 
enthusiasm for peptide-based vaccination regimens in the setting of cancer and a variety of 
clinical trials are being conducted based on the use of peptides (Aurisicchio and Ciliberto, 
2010). In this respect promising results in phase II studies have been obtained by Immatics 
(www.immatics.com) . This technology consists in the vaccination of patients with multiple 
tumour-associated peptides (TUMAPs) that can be isolated from tumour specimens and 
identified by mass spectrometry (Dengjel et al, 2006). The most advanced product, IMA901, 
a combination of several TUMAPs for the treatment of renal cell carcinoma, completed a 
Europe-wide multi-center Phase II clinical trial and has recently commenced a Phase III trial. 
Another advanced peptide vaccine is L-BLP25 (Stimuvax) currently under development by 
MerckSerono. L-BLP25 is a peptide vaccine that targets the exposed core peptide of MUC1, a 
mucinous glycoprotein which is overexpressed and aberrantly glycosylated in many human 
malignancies. MUC1 is associated with cellular transformation and can confer resistance to 
genotoxic agents. In preclinical studies, L-BLP25 induced a cellular immune response 
characterized by T-cell proliferation in response to MUC1 and production of IFN- 
(reviewed in Gridelli et al., 2009). Phase I and II trials have established the dose and 
schedule of the vaccine as well as its excellent safety profile. A randomized phase II trial of 
maintenance L-BLP25 versus best supportive care in patients with stage IIIB/IV non-small 
cell lung cancer showed a strong survival trend in favor of L-BLP25 (median survival, 30.6 
versus 13.3 months) in a subgroup of patients with locoregional stage IIIB disease (Butts et 
al., 2011). These promising results are being tested in three phase III trials (START, INSPIRE 
and STRIDE). The START and the INSPIRE studies are Phase III, multi-center, randomized, 
double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety and 
tolerability of Stimuvax in subjects suffering from unresectable, stage IIIA or IIIB non-small 
cell lung cancer (NSCLC) who have had a response or stable disease after at least two cycles 
of platinum-based chemo-radiotherapy. The primary endpoint of the START study is 
overall survival (OS). STRIDE is a randomized, double-blind, controlled, multi-center Phase 
III study designed to determine if Stimuvax can extend progression free survival in patients 
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treated with hormonal therapy who have inoperable, locally advanced, recurrent or 
metastatic breast cancer. Overall survival, quality of life, tumour response and safety will 
also be assessed in this study. 
3.1.5 Protein vaccines 
Isolated recombinant proteins have been successfully employed for antiviral vaccines. 
However, soluble proteins are poorly immunogenic and require appropriate adjuvants and 
delivery systems to induce the desirable level and type of immune responses. For optimal 
performance, antigen delivery vehicles should closely mimic the composition and 
immunological processing of actual pathogens; they should actively or passively target 
APCs such as DCs; protect the antigenic protein from spontaneous degradation; direct the 
nature of the resulting immune response (i.e., cellular versus humoral responses) and, lastly, 
induce APC maturation by interacting with elements of the innate immune system such as 
Toll-like receptors (TLRs). Several strategies have been reported including directly 
conjugating TLR ligands to protein antigens or co-encapsulating immunostimulatory agents 
and proteins in liposomes or hydrophobic polymeric particles (Beaudette et al., 2009).  
The most advanced approach is the one being pursued for the development of MAGE-A3 
antigen specific immunotherapy (ASCI). MAGE-A3 ASCI is a therapeutic cancer vaccine 
directed against tumour antigen MAGE-A3, which is overexpressed in subset of patients 
affected by various cancers, and is being developed by GSK (Tyagi and Mirakhur, 2009). The 
vaccine is delivered as highly purified recombinant protein in conjunction wih GSK’s own 
proprietary adjuvant System. The most advanced development for the MAGE-A3 vaccine is 
a Phase III  trial called MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell Lung Cancer 
Immunotherapy), which began in October 2007 aimed at recruiting 2270 patients 
randomized to ASCI or placebo. The objective of the MAGRIT trial is to investigate the 
efficacy of MAGE-A3 ASCI in preventing cancer relapse, when administered after tumour 
resection, in patients with MAGE-A3 positive stages IB, II and IIIA NSCLC and is going to 
be the largest-ever trial in the adjuvant treatment for NSCLC. Results of the MAGRIT trial 
are expected in late 2011 and may lead to  registration of this product in the coming years. 
3.2 Genetic vaccines 
Genetic vaccines represent promising methods to elicit immune responses against a wide 
variety of antigens, including TAAs. A variety of vectors have been utilized in the past, each 
of them presenting advantages and drawbacks with respect to "classic" protein-based 
vaccines. The main advantage of genetic vaccines is that they allow a) endogenous 
expression of the antigen of interest by muscle and/or antigen-presenting cells, which 
maximize antigen processing through the endogenous pathway and epitope display on 
MHC class I molecules, and b) easy molecular engineering of the targeted tumour antigen 
which help to boost significantly self-antigen immunogenicity. 
3.2.1 Viral vaccines 
Viral infection results in the presentation of virus-specific peptides in association with both 
MHC class I and MHC class II on the surface of infected cells. Based on this observation, 
several strategies have been designed to use viruses as immunization vehicles to elicit 
antigen-specific immune responses. In this approach, the cDNA encoding one or more 
antigens, is inserted into a viral vector. The resulting recombinant viruses are used as 
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vaccine, obtaining the in vivo expression of the selected antigen(s) and its presentation to the 
immune system. A variety of gene therapy viral vectors have been adapted to cancer 
immunotherapy. For vaccination purposes, the ideal viral vector should be safe with respect 
to disease-causing potential, transmissibility and long-term persistence in the host. It should 
enable efficient presentation of expressed antigens to the immune system while preferably 
exhibiting low intrinsic immunogenicity so that it can be administered repeatedly to boost 
relevant specific immune responses, often necessary to break immune tolerance to self 
antigens.  
Tumour antigen DNA sequences have been inserted into attenuated pox viruses that are 
unable to replicate in mammalian hosts (such as modified vaccinia Ankara, fowlpox, or 
canarypox). Vaccinia poxvirus (VV) was demonstrated to be safe and very effective in the 
induction of potent cellular and humoral immune response in several tumour model 
systems (Gómez et al. 2011). For Carcinoembryonic Antigen (CEA), VV as well as ALVAC, a 
variant of the canary poxvirus, have been successfully used in colorectal cancer patients. As 
an avian virus, ALVAC has an advantage over vaccinia in that it is unable to replicate in 
human cells and thus has a very favorable safety profile. Combination of vaccinia followed 
by multiple injection of ALVAC revealed to be efficient in terms of elicited anti-CEA 
immune response and overall patient survival (Marshall et al., 2005). Another successful 
story of a vaccine based on this technology is PROSTVAC-VF (Bavarian Nordic, Kvistgård, 
Denmark). PROSTVAC-VF is a vaccine against Prostate Specific Antigen (PSA) that includes 
a number of costimulatory molecules. Three well-characterized costimulatory molecules 
were found to be synergistic when added to the poxvirus system. This triad, which includes 
B7.1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58), is designated as TRICOM and has been 
added to both the vaccinia priming vector and the fowlpox boosting vector. With PSA as the 
encoded antigen, this configuration constitutes PROSTVAC-VF, vaccinia-PSA-TRICOM, and 
fowlpox-PSA-TRICOM. Interestingly, a randomized, controlled, and double-blinded phase 
II study was designed and powered for the short-term end point of PFS, and it failed to find 
an association between treatment arm and progression. However, a strong association 
between treatment arm and OS was observed (Kantoff et al., 2010). The estimated hazard 
ratio is 0.56 (95% CI, 0.37 to 0.85), and the observed difference in median survival of 8.5 
months suggests a significant therapeutic benefit. PROSTVAC-VF immunotherapy is, 
therefore, a promising approach, and a larger pivotal phase III trial is being planned. 
Another Poxvector based vaccine is Trovax, a vector directed against a tumour enriched 
surface marker named 5T4 (Kim et al, 2010). Clinical trials with Trovax showed good safety 
profile, immunologic responses to the target antigen and efficacy in relation  to a defined 
biomarker strategy (see section 4.2). TG4010 is an MVA vector developed by Transgene 
(Strasbourg, France) that incorporates the MUC1 antigen, which is overexpressed in the 
majority of cancers. A second gene, interleukin-2 is also incorporated as an immune 
stimulus. The vaccine has been tested in breast, kidney, prostate and lung cancers with 
encouraging results in phase II. For RCC, thirty-seven patients with progressive, MUC1-
positive tumours received TG4010 108 pfu/inj weekly for 6 weeks, then every 3 weeks until 
progression, when TG4010 was continued in combination with interferon-ǂ2a and 
interleukin-2. Assessments included clinical response (primary endpoint), safety, time to 
treatment failure (TTF), OS, and immune response. No objective clinical responses occurred, 
but median OS was 19.3 months for all patients and 22.4 months for combination therapy 
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recipients. MUC1-specific CD8+ T cell responses were associated with longer survival 
(Oudard et al., 2011).  
Another emerging viral system for vaccination is Adenovirus (Ad). Ads are very efficient 
vehicles for gene delivery and have been extensively characterized for gene therapy 
purposes (reviewed in Dharmapuri et al., 2009). Ad gene therapy products have recently 
been demonstrated to be safe, well-tolerated and capable of successful gene transfer to 
target cells. The high immunogenicity of E1-deleted first generation Ad recombinants has 
largely excluded their use for somatic gene therapy but re-directed their development as 
vaccine carriers. Ad vaccines have been shown to induce the highest degree of B- and CD8+ 
T-cell responses in experimental animals, including rodents, canines, and primates against a 
variety of immunogens derived from a variety of infectious agents (e.g., viruses, parasites, 
or bacterial pathogens) and tumour cells, including tumour-associated antigens (TAAs). 
Most clinical trials with Ad vectors have been conducted in oncology. Among the others, 
intratumour (IT) injections of Ad containing the wild-type p53 tumour suppressor gene 
showed clinical efficacy when combined with chemotherapy and led to the clinical 
development of Advexin® and Gendicine®. Advexin and Gendicine® are recombinant Ad5 
vectors with an E1 region that is replaced by a human wild type p53 expression cassette 
containing a Cytomegalovirus (CMV) or Rous sarcoma virus (RSV) promoter, respectively. 
In October 2003, the State Food and Drug Administration (SFDA) of China approved 
Gendicine as the first commercialized gene therapy product in the world. Another example 
is Onyx-015, the first engineered replication-selective virus to be used in humans. It is an 
Ad2/Ad5 hybrid with deletions in E1B and E3B region and replicates exclusively in cells 
with inactive p53, activated p14ARF and late viral mRNA transport. Onyx-015 has been 
tested in more than 15 clinical trials by direct IT injection (up to 5 × 109 vp) and resulted in 
transient antitumoural effects (objective response rate 14%). 
For development of cancer vaccines, several groups are currently assessing the immunologic 
and clinical activity of Ad vectors expressing TAAs, such as prostate serum antigen (PSA), 
HER-2/neu, carcinoembryonic antigen (CEA) and telomerase (hTERT) (see 
www.clinicaltrials.gov). It will be of great interest to verify how local and systemic 
suppression exerted by the tumour itself as well as pre-existing immunity to Ad will impact 
the outcome of these studies.  
In conclusion, viral vectors appear promising tools for cancer vaccines. From a practical 
standpoint, viral vectors also meet criteria that enable their large scale industrialization. 
These include; efficient growth on a cell substrate acceptable to regulatory authorities; total 
genetic stability with respect to attenuation and presence of the foreign gene(s), scalability to 
large doses; easy purification of the vector virus away from cellular debris, and stability in 
the final formulation. 
3.2.2 DNA plasmid vaccines 
The inoculation of plasmid DNA coding for a protein antigen by means of a simple 
intramuscular or intradermal injection currently represents an easily performed vaccine 
approach that is safe for host and relatively inexpensive. DNA delivery vehicles contain a 
gene expression cassette bearing the coding region of an antigen gene regulated by a 
promoter usually with constitutive activity (like the cytomegalovirus early enhancer-
promoter). Simple injection of naked DNA sequences results in gene expression and the 
generation of immune responses. A possible mechanism of how DNA immunization works 
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is the following: the protein antigen is  produced by the target cells (usually skeletal 
myocytes or dermal fibroblasts, depending upon the injection route) that usually lack the co-
stimulatory molecules needed as part of the CTL activation process. Subsequently, the 
antigen is taken up by host APCs, processed, and cross-presented to the immune system in 
the draining lymph nodes, although direct transfection of rare APCs residing at the injection 
site has also been demonstrated (Liu, 2011). 
In mouse models, DNA vaccines have been successfully used to generate strong cellular 
immune responses against a wide variety of tumour antigens and to exert a preventive or 
therapeutic effect on tumour growth (Liu, 2011). However, clinical trials for DNA vaccines 
have shown that, albeit immune responses can be generated in humans, there is a need for 
increased potency if this vaccine technology is to be effective. The reasons for the failure of 
DNA vaccines to induce potent immune responses when scaled up from mice to man have 
not been fully elucidated. However, it is reasonable to assume that low levels of antigen 
production, inefficient cellular delivery of DNA plasmids and insufficient stimulation of the 
innate immune system have roles in low potency of DNA vaccines (Ulmer et al., 2006). In 
the design of more potent DNA vaccines, clearly regimens, plasmid dose, timing, adjuvants, 
alternative delivery systems and/or routes of vaccination are being considered. Methods for 
enhancing DNA plasmid delivery include tattooing, Gene gun, Ultrasound, Laser and DNA 
electroporation (reviewed in Bolhassani et al., 2011). In particular, here we will focus our 
attention on DNA electroporation. 
3.2.3 DNA electroporation  
In vivo electroporation of plasmid DNA (DNA-EP) has emerged as a safe method resulting 
in greater DNA uptake leading to enhanced protein expression in the treated muscle, and in 
a concomitant increase in immune responses to the target antigen in a variety of species 
(Aurisicchio et al., 2007; Peruzzi et al., 2010a). For its properties, DNA-EP is a desirable 
vaccine technology for cancer vaccines since it is repeatable several times, as required for the 
maintenance of anti-tumour immunity (Peruzzi et al., 2010b). This approach uses brief 
electrical pulses that create transient “pores” in the cell membrane, thus allowing large 
molecules such as DNA or RNA to enter the cell cytoplasm. Immediately following 
cessation of the electrical field, these pores close and the molecules are trapped in the 
cytoplasm (Andre et al., 2010). Typically, milli- and microsecond pulses have been used for 
EP. In addition to the increased permeability of target cells, EP may also enhance immune 
responses through increased protein expression, secretion of inflammatory chemokines and 
cytokines, and recruitment of APCs at the EP site (Liu, 2011). As a result, both antigen-
specific humoral and cellular immune responses are increased by EP mediated delivery of 
plasmid DNA in comparison with levels achieved by intramuscular injection of DNA alone. 
Indeed, the addition of in vivo EP has been associated with a consistent enhancement of cell-
mediated and humoral immune responses in small and large animals, supporting its use in 
humans.  
Several devices have been developed for DNA-EP. Cytopulse has developed two clinical 
vaccine delivery systems: DermaVax™ and Easy Vax™. Easy Vax™ primarily targets the 
epidermis layer of skin and has been used in mass-scale prophylactic virus vaccination. In 
contrast, Derma Vax™ primarily targets the dermis layer of skin. Clinical trials in progress 
and planned using DermaVax™ include  Prostate cancer (Phase I/II) and Colorectal cancer 
(Phase I/II). In this study, DNA vaccine was delivered by intradermal electroporation to 
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treat colorectal cancer (El-porCEA; ID: NCT01064375). The purpose of this study was to 
evaluate the safety and immunogenicity of a CEA DNA immunization approach in patients 
with colorectal cancer. Altogether, the electroporation with DNA vaccines has been 
investigated in several clinical trials for cancer therapy. They include: (1) Intratumoural IL-
12 DNA plasmid (pDNA) [ID: NCT00323206, phase I clinical trials in patients with 
malignant melanoma]; (2) Intratumoural VCL-IM01 (encoding IL-2) [ID: NCT00223899; 
phase I clinical trials in patients with metastatic melanoma]; (3) Xenogeneic tyrosinase DNA 
vaccine [ID: NCT00471133, phase I clinical trials in patients with melanoma]; (4) VGX-3100 
[ID: NCT00685412, phase I clinical trials for HPV infections], and 5) IM injection prostate-
specific membrane antigen (PSMA)/pDOM fusion gene [ID: UK-112, phase I/II clinical 
trials for prostate cancer] (Bodles-Bakhop et al., 2009). Inovio (Oslo, Norway) has developed 
electroporators suitable for muscle DNA-EP, such as MedPulser®. Plasmid V930 is DNA 
vaccine candidate being developed by Merck. This vaccine is designed to target cancers 
expressing the antigens HER-2/neu and/or CEA, which include breast, colorectal, ovarian, 
and non-small cell lung cancer (ID: NCT00250419). V934 is a DNA plasmid that encodes 
human Telomerase (hTERT). The biologic is a Merck proprietary, therapeutic DNA vaccine 
candidate designed to target cancers expressing the antigen hTERT (ID: NCT00753415), 
including non-small cell lung carcinoma; breast cancer; melanoma; upper GI tract (e.g. 
esophagus, stomach, gallbladder) in collaboration with Geron Corp. (Menlo Park, CA, USA). 
Both vaccines are undergoing Phase I studies using MedPulser® DNA Delivery System in 
combination with Ad vectors.  
Attempts to further enhance immune responses elicited by DNA vaccines are focusing on 
the use of codon optimization in order to enhance expression in eukaryotic cells. In fact, the 
potency of current gene delivery methods that include plasmid DNA and viral vectors can 
also be improved through increasing the expression efficiency of the encoded antigens. 
Elevated percentages of AU in human mRNA have been shown to result in instability, 
increased turnover, and low expression levels of the encoded proteins. These findings have 
prompted modification of the target gene coding sequence through reduction of the AT 
content with the assumption that these modifications could result in improved mRNA 
stability and increased expression. These changes have been justified by the observation that 
for highly expressed genes, G or C is generally preferred over A or T. In fact, optimization of 
the codon usage of the target gene has been shown in a variety of experimental systems to 
lead to enhanced expression and increased immunogenicity (Aurisicchio et al., 2007; Peruzzi 
et al., 2010a, b).  
Another strategy to enhance the efficacy of DNA vaccine is the development of gene fusions 
in which antigens are linked to various immunoenhancing elements (reviewed in Stevenson 
et al., 2004). The enhancement of immune responses is particularly relevant for cancer 
vaccines because of the limited immunogenicity of tumour antigens and the need to 
overcome tolerance. Enhancement of immune response to target antigens has been 
demonstrated in animal models by vectors encoding antigens fused to heat shock protein 70 
(HSP70), the Fc portion of IgG1, lysosome-associated membrane protein (LAMP), the 
universal helper T (Th) epitope from tetanus toxin (DOM) (Facciabene et al., 2006) and Heat 
labile enterotoxin B from E. Coli (Facciabene et al., 2007). A DOM-PSMA fusion DNA 
vaccine delivered via DNA-EP resulted in highest antibody response to DOM in prostate 
cancer patients (Low et al., 2009), while LTB fusions are currently being evaluated in the 
clinical trials for CEA and hTERT cited above.  
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In conclusion, DNA vaccines have several promising features. They are simpler and cheaper 
to produce. DNA immunization is not associated with anamnestic immune responses 
against the vector. On the other hand, it appears that efficacy must be improved, especially 
for cancer vaccines targeting 'self' antigens. 
3.3 Heterologous prime/boost 
There are emerging evidences that vaccination schedules comprising more than one 
delivery method against the same antigen(s) (i.e., genetic vectors, genetic vector/protein, 
genetic vector/peptides, etc.) may be beneficial to overcome the ‘therapeutic immunity’ 
threshold and adequately harness the immune system to fight cancer. In particular, genetic 
vectors, if appropriately combined with each other and with other agents 
(immunomodulators and/or chemotherapy) hold promise for clinical development 
(reviewed in Lu et al., 2009). 
The sequential administration of DNA and a viral vector in different combinations may 
result in synergistic immune activation. Preclinical murine and primate models have shown 
that this heterologous prime-boost regimen induces 10- to 100-fold higher frequencies of T 
cells than do naked DNA or recombinant viral vectors alone (Ribas et al., 2003). In addition 
to the enhanced immune response, the therapeutic proof of concept of DNA/viral vector 
combination has recently been achieved in dogs affected by B cell lymphoma (Peruzzi et al., 
2010b). In this study, the best performing vaccination schedule consisted of Ad followed by 
DNA-EP boosters, concurrently with chemotherapy (see also section 4.1). Another strategy 
is the sequential administration of two different viral vectors carrying the same tumour 
antigen gene, which bypasses the limitation of the development of neutralizing antibodies to 
the viral backbone by boosting with a different vector without shared viral epitopes (see 
paragraph 3.2.1). 
4. Cancer vaccines clinical development 
Due to the complexity of tumour immunology, the success of cancer vaccines points to 
important considerations for clinical development: (1) evaluation of vaccines in predictive 
preclinical animal models. (2) Biomarker strategies for patient selection. This turns to be a 
crucial aspect as revealed by the experience of different cancer vaccine products under 
evaluation (see next paragraph);  (3) value of vaccinating at early stages of cancer 
progression. Advances in early cancer detection methods and the development of 
efficacious cancer vaccines will allow vaccination of patients with various types of cancer at 
early stages of disease, when they still have an intact immune system. This may become the 
most promising strategy for preventing tumour progression. (4) use of heterologous prime-
boost technologies (see previous paragraph). (5) combination with other therapies. Some 
classes of chemotherapy drugs could act as immunomodulators by affecting antigen cross-
presentation, inducing a cytokine storm, reducing the number of regulatory T cells and 
activating homeostatic lymphoid proliferation. (6) autoimmunity as a possible side effect of 
cancer immunotherapy. In those instances when intense immunotherapy is necessary the 
incidence of autoimmunity in early or especially in advanced cancer should be evaluated in 
the short or long term following immunotherapy. 
4.1 Pre-clinical models 
Cancer immune therapy and its translation to the clinic are strictly dependent on efficient 
vaccine technology, delivery systems and evaluation in appropriate pre-clinical models. For 
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cancer vaccines the most widely used models for immunologic and anti-tumoural studies 
are transgenic rodents expressing the human TAA which show central and/or peripheral 
tolerance to the antigen of interest (see Fig. 1). The mouse is an excellent and reproducible 
system: mice from a given strain are inbred, with same MHC-I, allow experimentation on a 
large number of subjects. The mouse immune system is well-known and all reagents are 
available. Nevertheless, the translational relevance of cancer vaccines additionally needs a 
suitable, outbred therapeutic large animal model. In fact, scaling up experimental protocols 
from rodents to humans is often not a straightforward procedure, and this particularly 
applies to cancer vaccines, where vaccination technology must be especially effective to 
overcome a variety of immune suppressive mechanisms.  
Nonhuman primates such as macaques are valid models to determine the safety and 
immunogenicity of candidate vaccines that are being developed for implementation in 
humans. In fact, the immune response is similar to that expected in humans. In the last two 
decades numerous immunogenicity studies have been performed in nonhuman primates 
utilizing pre-clinical candidate vaccines, most of them utilizing recombinant proteins of 
bacterial or viral origin as immunogen or genetic vectors coding for viral antigens (Shiver et 
al., 2002; Montgomery et al., 1993; Jeong et al., 2004). This is a reasonable approach when 
dealing with bacterial or viral diseases, where the organism recognizes the antigen as an 
exogenous protein and consequently the elicited immune-response is generally strong and 
effective against the target pathogen. Similarly, other studies involving the use of TAAs 
have been conducted with human proteins or vectors encoding for human TAAs: in these 
reports, the elicited immune response is not expected to be fully predictive of the possible 
outcome in human patients, since the antigen is recognized as a non-self protein. Therefore, 
the evaluation of the immune response against the ‘self’ antigen requires cloning of the 
nonhuman primate ortholog gene and evaluation of a technology able to break immune 
tolerance (Aurisicchio et al., 2007; Fattori et al., 2009). Still, evaluation of antitumour efficacy 
cannot be performed in nonhuman primates.  
Another emerging model in oncology is the dog. The dog is extensively used in drug 
discovery and development because of its similarities to human anatomy and physiology. 
Compared with other animal models, dogs naturally develop cancers that share many 
characteristics with human malignancies (Paoloni et al., 2008). Cancers in pet dogs are 
characterized by tumour growth over long periods of time in the setting of an intact 
immune system, interindividual and intra-tumoural heterogeneity, the development of 
recurrent or resistant disease, and metastasis to relevant distant sites. Thanks to their large 
population size, cancer rate in pets is sufficient to power clinical trials, including assessment 
of new drugs. Examples include non-Hodgkin lymphoma, osteosarcoma, melanoma, 
prostate carcinoma, lung carcinoma, head and neck carcinoma, mammary carcinoma and 
soft tissue sarcoma, which share similar histological appearance, tumour genetics, biological 
behavior and response to conventional therapies with human cancers. With the recent 
release of the canine genome sequence, the dog is now also amenable to comparative 
genomic and expression analysis, including tumour samples (Uva et al., 2009) . However, to 
date the application of cancer vaccines in dogs has been poorly explored. A xenogeneic 
DNA-based vaccine strategy for melanoma is the only example in the setting of minimal 
residual disease in dogs (Bergman et al., 2006) that led to the successful approval and the 
commercial launch of a veterinary biological (Merial US). Furthermore, recently we have 
been able to successfully evaluate a heterologous prime-boost Ad-vector /DNA-EP based 
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vaccine against telomerase in canine subjects affected by B cell lymphoma (Peruzzi et al., 
2010b). Unfortunately, the canine immune system is not deeply characterized and there are 
not many tools available to further evaluate the impact of a vaccination strategies. However, 
we expect that pet dog nonclinical studies will increasingly gain interest to help a better 
definition of the safety and activity of new anticancer agents and the identification of 
relevant biomarkers associated with response or exposure to these drugs. 
 
Animal Models for Cancer Vaccines
Basic requirements:
 Appropriate expression of the antigen
– Tissue distribution
– Expression level
 Immunologically tolerant to the 
antigen
 Spontaneous tumorigenesis 
 Transgenic mice
– Immune system well 
characterized
– Ease of manipulation
– Can develop spontaneous 
tumors
– Small size
 Rhesus monkey
– Larger size 
– Immune system similar to 
Humans
– Efficacy studies difficult 
to perform
 Dogs
– Similar tumor gene 
expression profile to humans
– Large number of cancer 
patients
– Immune system less 
characterized
 
Fig. 1. Animal models for Cancer Vaccines. Advantages and drawbacks of each model are 
indicated. 
4.2 Biomarker strategies 
Drug failures in Oncology often originate from a lack of understanding of the biology of the 
drug, its mechanism of action (MOA), the complexity of patient physiology, and inadequate 
characterization of patient tumours. Poor understanding of the criteria required for patient 
selection for the drug may lead to misapprehensions of the drug’s potential for safety and 
efficacy. It is these misapprehensions that can persist through to late development until the 
clinical program crashes in a late and costly failure. Clearly, there is an urgent need for 
detailed information on new anticancer drugs to help make critical development decisions 
at the earliest possible point, speeding up the development process and enabling valuable 
time and resources to be placed where they can do the most good. 
Molecular biomarkers are widely recognized as being integral to this solution. They provide 
a set of tools which can provide invaluable information to support two major development 
concerns: 
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1. Does the drug perform according to the expected mechanism of action? 
2. Which patients will experience benefit in disease management utilizing the drug? 
Thus, appropriately selected biomarkers can be used to confirm the MOA, while patient 
selection biomarkers can be used to guide the selection of the most appropriate patients for 
therapies. Correct use of biomarkers for patient selection can enrich the treatment 
population by identifying those most likely to benefit from the treatment. This reduces the 
risk to the non-responder population and, by allowing earlier assessment of therapeutic 
efficacy, substantially shrinks the costs of development. 
Over the past two decades molecular biomarkers have become established components of 
clinical research in a way few could have foreseen. Today > 50% of new molecular entities 
are estimated to have a biomarker element also in development (Carden et al, 2010). 
Nowadays the most successful examples of biomarkers for patient selection are HER2 
positivity for treating breast cancer patients with Herceptin® and lack of KRAS mutations 
for treatment of colorectal cancer patients with Erbitux® or Vectibix®. They have 
completely different histories. The development of Herceptin was guided from its earliest 
stages by the use of the selection biomarker – HER2 – as an integral part of the original 
development plan for the product (Pietras et al, 1998). However, in the case of Erbitux® 
(cetuximab) and Vectibix® (panitumumab) in colorectal cancer, the original hypothesis that 
the level of epidermal growth factor receptor (EGFR) expression was critical for success of 
the antibody turned out to be wrong. Only recently the crucial role of KRAS wild type (or 
non-KRAS mutant carrying) tumour cells has been found to be a necessary element for 
Erbitux functioning and thus has been introduced into the drug’s label (http:// 
www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm ). 
All the considerations above need to be applied also to the development of cancer vaccines 
and cancer immunotherapeutics in general. It is inconceivable nowadays to imagine that a 
new immunotherapy will be efficacious when administered to all patients affected by a 
given cancer pathology. Therefore a rigorous biomarker strategy is absolutely essential to 
avoid failures in cancer vaccines development (Gajewski et al, 2010; Disis, 2011). As a 
corollary, we believe that one of the main reasons for the several failures of previous cancer 
vaccines in phase III is the lack of biomarkers for patients selection, and this in spite of 
radiological evidences of direct anti-tumour efficacy observed in subsets of patients during 
precedent Phase II trials. Therefore, several attempts are currently being made to rescue 
vaccines “failed” in Phase III trials through a rigorous retrospective analysis of data 
collected in Phase III in order to identify biomarkers that can allow to predict patients who 
will most benefit from treatment, and then to restart Phase II and Phase III development.  
This is the case for example of Trovax (see paragraph 3.2.1). Trovax was developed through 
a series of Phase I an II trials, until it was brought into a Phase III trial called TRIST (TroVax 
Renal  Immunotherapy Trial) in patients with advanced or metastatic renal cell carcinoma. 
The study enrolled 733 patients divided in two arms: 1) Trovax + IL2 or IFN or sunitinib; 2) 
Placebo + IL2 or IFN or sunitinib (Amato et al, 2010). The primary predefined endpoint, 
namely survival (80% power, HR= 0.725; = 0.05), was not met. However , subsequent 
analysis showed survival advantage in certain subsets of patients, and this opened up to 
studies aiming at identifying factors which could maximize benefit. In particular 
immunological monitoring suggested that 5T4 antibody responses were associated with 
increased survival (Harrop et al, 2011). However, it was necessary to show that 5T4 
antibody responses was not simply linked to the general health status of the patients. This 
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was possible through the identification of an “immune response surrogate”, capable of 
predicting antibody responses with a reasonable level of accuracy. This was indeed 
identified in baseline platelet levels. In fact elevated platelet levels inversely correlate with 
anti 5T4 antibody responses and therapeutic efficacy. This new biomarker is currently being 
analyzed in additional ongoing trials and will likely be used to inform future strategies for 
renewed Phase II/III development of TroVax.  
As mentioned in the introduction section, ipilimumab, the fully human monoclonal 
antibody directed against CTLA-4 has had a luckier developmental fate and was recently 
approved by FDA for the treatment of metastatic melanoma. A  3.7-month survival benefit 
was observed in the registration PhaseIII trial in the ipilimumab arm vs control gp-100 
peptide vaccine arm was achieved (hazard ratio 0.68; P = 0.003), which met the predefined 
primary endpoint (Hodi et al, 2010). However if we look only at tumour responses only a 
minority of patients treated with ipilimumab or with the other anti CTLA-4 antibody under 
development, tremelimumab,  achieve radiographic responses (Sarnaik and Weber, 2009). In 
the search of biomarkers capable of predicting early efficacy of these two antibodies 
immunological monitoring has been an integral part of their clinical development. 
Approaches to immunological monitoring have included: 1) monitoring the frequency of 
specific populations of cells in peripheral blood or tumour; 2) monitoring changes in 
expression levels of specific markers on immune cells; 3) quantifying antigen specific 
immune responses including antibody and CD8+ or CD4+ T cell responses; 4) monitoring 
changes in peripheral cytokine levels of cytokines produced by specific immune cell 
populations. This has led to the identification of several endpoints that may correlate with a 
variety of clinical parameters (reviewed in Callahan et al, 2010). The most robust correlation 
to date is with the rate of absolute lymphocyte counts (ALC), which was shown to correlate 
with clinical benefit (Berman et al, 2009). Also, inducible costimulator (ICOS) a member of 
the immunoglobulin gene family, seems to be involved. In some studies a correlation 
between increased frequency of circulating CD4+ICOShigh T cells and Overall Survival has 
been shown (Chen et al, 2009; Vonderheide et al, 2010; Charton et al, 2010). Promising 
biomarkers also appear to be increases in CD54RO and HLA-DR on circulating CD4+ and 
CD8+  T cells (Comin-Anduix et al, 2008), poly-epitope antigen specific immune responses 
(Yuan et al, 2008) and degree of intratumoural Treg infiltration (Ribas et al, 2009). Finally 
perhaps the most recent but probably most promising biomarker appears to be the change 
in circulating levels of Th17 as shown in a recent study on 75 patients (Sarnaik et al, 2011), 
where higher changes in Th-17 inducible frequency was a surrogate marker of freedom from 
relapse (p=0.047). These biomarkers have been so far identified in small retrospective trials, 
but their validation awaits larger prospective studies. Also, another present limitation of 
these biomarkers is that they belong more to the category of efficacy biomarkers than to that 
of stratification biomarkers and therefore, do not look as promising tools to stratify patients 
that are expected to better respond to therapy. 
A clever biomarker strategy has been applied for MAGE-A3 ASCI by GSK (see paragraph 
3.1.5). The MAGRIT study applies stringent patient stratification criteria based upon the 
level of expression of MAGE-A3 in patients’ tumours (approximately 40% of NSCLC 
patients), which are believed to have greater chances of responding to therapy, mirroring 
the same strategy adopted during Herceptin® development. Furthermore, during the early 
phases of MAGE-A3 ASCI clinical development a multiple gene signature predictive of 
response to therapy was derived with an unbiased approach from microarray analysis of 
RNA extracted from peripheral lymphocytes of treated patients, in the attempt to establish a 
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correlation  between gene expression and disease relapse. The MAGRIT trial will have as an 
additional objective the validation of this predictive signature in a prospective manner.  
4.3 Combination therapies 
The greatest potential for cancer vaccines will derive from the possibility to combine these 
treatments with existing and forthcoming therapeutics in order to create synergies while 
mitigating side effects (Andersen et al, 2010). Understanding the molecular basis for 
synergies poses significant scientific challenges, together with the definition of the best 
protocols for combinations. The establishment and optimization of dosing and scheduling of 
multiple treatments will require intensive pre-clinical studies as well as the conduct of well 
designed clinical study protocols with the consequence of significantly increasing 
development costs. Furthermore, for the combination of experimental drugs the ability to 
conduct combination studies will require that Companies that are commercially pursuing 
different drugs and vaccine candidates must come to specific agreements. 
4.3.1 Combining vaccines with chemotherapy 
It is now clear that chemotherapy, instead of having a general immunodepressant effect, 
when given in particular combination schedules, can have a potent immunostimulatory 
effect and may enhance cancer vaccine efficacy. Several pre-clinical studies have been at the 
basis of what is now called chemoimmunotherapy, a strategy which is structured upon the 
possibility to enhance cancer vaccine efficacy through well studied combinations with 
available chemotherapeutic agents. Promising clinical results have been obtained, which are 
waiting for confirmation in larger randomized trials (Zitvogel et al, 2008).  
A leading example is that of cyclophosphamide (CTX), an alkylating agent that has been 
used for a long time at high dosages as a potent cytotoxic and lymphoablative drug. In 
recent years careful studies have shown that low doses CTX (also called metronomic CTX) 
have instead immunostimulatory and antiangiogenic effects, opening up new applications 
for cancer immunotherapy. By promoting IFN secretion, CTX influences dendritic cells 
homeostatis, leading to preferential expansion of CD8+ DCs, i.e. the main subset involved 
in cross-presentation of cell-derived antigens (Schiavoni et al, 2011; Moschella et al, 2011). 
Furthermore CTX induces tumour cell death with consequent DCs uptake of tumour 
apoptotic material, and CD8+ T-cell cross priming. Finally CTX induces a T-helper 17 (Th17) 
status, capable of shifting the Treg/Teffector equilibrium in favor of tumour regression 
(Sistigu et al, 2011). Another drug that is being combined with cancer vaccines with 
promising results is dacarbazine, due to its known effect in stimulating cytokine production, 
modulating Treg numbers and favouring homeostatic proliferation of effector T cells 
(Nisticò et al, 2009).  
Chemotherapy-induced cell death can also be qualitatively immunogenic through 
upregulation of surface calreticulin. This process, called immunogenic apoptosis has been 
observed with chemotherapeutic agents such as oxaliplatin and anthracyclines and is 
activated by pre-apoptotic ER stress. Calreticulin, a protein usually residing in the 
endoplasmic reticulum is translocated onto the plasma membrane surface and triggers cell 
engulfment by dendritic cells and tumour associated antigens presentation (Zitvogel et al, 
2010). Finally, other chemotherapeutic agents such as gemcitabine have been shown to favor 
depletion of TAMs and may enhance vaccine efficacy through removal of their negative 
regulation on effector T cells (Suzuki et al, 2007). 
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4.3.2 Combining vaccines with immunomodulators 
From the mechanistic standpoint these are the combinations that should work best. 
Depending upon their mechanism of action immunomodulators are expected either to 
increase vaccine immunogenicity by potentiating antigen-specific CD8+ and/or CD4+ T cell 
responses, or to increase vaccine effectiveness by impairing one or more of those 
immunosuppressive mechanisms that operate at the level of tumour microenvironment. It 
was unfortunate that these expectations were not met in the Phase III trial that led to 
registration of Ipilimumab. In that 3 arms trial, Ipilimumab alone was as effective at 
increasing OS as the combination of Ipilimumab plus a peptide gp100 vaccine (Hodi et al, 
2010). In other words, adding a therapeutic melanoma vaccine on top of Ipilimumab did not 
provide additional advantage. Several are the possible explanations of this failure, but we 
believe, as discussed above (see sestion 3.1.4) that peptide vaccines, especially those 
monospecific, i.e. directed against a single epitope, are not potent enough to show efficacy, 
in particular in large trials like this one, where no patients stratification criteria are being 
applied.  
Nevertheless, we believe that vaccines plus immunomodulators combinations hold a great 
potential; however, they need to be studied in detail starting from rigorous preclinical 
studies. Furthermore, success of the same immunomodulators in one combination cannot be 
automatically extrapolated to another combination, because this may be affected by the 
combined vaccine/immunomodulators mechanism of action, and by the disease under 
study. For example we have observed that the same immunomodulators, namely an IMO 
TLR9 agonist exerts different effects when co-delivered with two genetic vaccines targeting 
different tumour antigens in two distinct pre-C models. In the BALB/NeuT model repeated 
vaccinations against HER2 with DNA electroporation plus systemic IMO administration 
proved to be the most effective treatment in the eradication of advanced mammary tumours 
(Aurisicchio et al, 2009). In contrast this was not the case when the same systemic IMO was 
co-delivered together with a genetic telomerase vaccine in an immunocompetent  mouse 
model of melanoma (Conforti et al, 2010). We believe this discrepancy is due to the fact that 
in the first case the anti-HER2 vaccine acts primarily through the induction of antitumoural 
antibody responses that are strongly enhanced by systemic IMO in mice (Aurisicchio et al, 
2009). In contrast, the telomerase vaccine mechanism of action is exerted via the induction of 
antigen-specific  cytotoxic CD8+ responses  (Mennuni et al, 2008) which are not increased by 
systemic IMO delivery.  
Among the most promising approaches to combinations is the one with agents capable to 
target Tregs (Golovina and Vonderheide, 2010). For example, in a transgenic CEA preclinical 
model we have observed that administration of an anti CEA vaccine plus an antibody 
against CD25 strongly enhanced CEA specific CD4+ and CD8+ antigen-specific immunity 
and exerted a strong tumour protection (Elia et al , 2007). Indeed a single infusion of 
daclizumab (Zenapax), a monoclonal antibody against CD25, in patients with metastatic 
breast cancer is associated with a strong and prolonged decrease of circulating CD25+ 
FoxP3+ Tregs. When a peptide vaccine was administered after Zenapax infusion, at the nadir 
of circulating Tregs, a strong generation of antigen-specific immunity was observed.  
In a very recent study, the administration of an agonistic CD40 antibody was shown, 
when combined with gemcitabine in a small cohort of patients with pancreatic ductal 
adenocarcinoma to induce tumour regressions (Beatty et al, 2011). Although in theory 
antibodies against CD40 are believed to act through reversion of immune suppression and 
induction of antitumour T cell responses, this was shown not to be the case in this trial 
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and in a relevant mouse model. Surprisingly the antibody seemed to act via a new and 
unsuspected mechanism of action, which consisted in the stimulation  of macrophages 
which infiltrated the tumours, became tumouricidal and facilitated depletion of tumour 
stroma.  
In conclusion, we believe that combinations of immunomodulators like Zenapax, TLR 
agonists, anti-CTLA4 antibodies, anti-PD1 antibodies, IDO inhibitors, etc. together with 
cancer vaccines, may have great potential to increase vaccine effectiveness and to prolong 
survival, but careful mechanistic studies have to be conducted to identify the best 
combination and the most appropriate delivery schedule for the two agents.  
4.3.3 Combining vaccines with other targeted therapies 
The availability of  an expanding repertoire of targeted therapies against cancer opens up 
tremendous possibility for combinations with therapeutic cancer vaccines. This is still a 
largely unexplored area. However we believe that, in parallel with the clinical progress and 
the increasing number of FDA and EMA approved vaccines, this area will be the object of 
extensive investigations. Based on the mechanism of action for example anti-angiogenic 
agents are expected to act synergically with cancer vaccines. The same concept can be 
applied to combinations with anti-apoptotic agents targeting Bcl-2 members. Finally we 
have to be aware that some cancer targeted therapies may exert a negative effect on immune 
responses. This is for example the case of sorafenib, which has been shown in a preclinical 
model to significantly affect the immunostimulatory capacity of DCs (Hipp et al, 2008), or of 
HDAC inhibitors which are able to increase the suppressive functions of Tregs (Akimova et 
al, 2010)  
4.3.4 Adverse effects of cancer Immunotherapy 
Cancer Immunotherapy has been initially advocated as being very specific  for cancer cells 
and to have fewer side effects than conventional therapies. This concept is confirmed by 
reports from cancer vaccines clinical trials of cases of patients experiencing complete 
responses in the absence of any serious adverse event (Suso et al, 2011). An even more 
significant example is the very benign toxicity profile of Sipuleucel-T (Plosker, 2011). It has 
to be pointed out however, when examining large trials, that vaccine-related adverse events, 
albeit rare and usually mild, are being observed. For example in a recent meta-analysis of 
500 cases of advanced cancer patients treated with therapeutic peptide vaccines, 6 severe 
adverse events (SAEs) were related to the vaccine itself (Yoshida et al, 2011). They consisted 
mainly in local skin reactions or cellulitis around the injection sites. In some cases, more 
systemic effects such as edemas of the head and neck regions, colitis, rectal bleeding and 
bladder-vaginal fistulae were reported.  
The occurrence of autimmuninty is particularly evident in the case of therapies with 
systemic immunomodulators more than with cancer vaccines. Indeed, Immune-related 
adverse events (IRAEs) are being commonly observed in patients after CTLA-4 blockade 
and most likely reflect the drug mechanism of action and corresponding effects on the 
immune system (Weber, 2007). Immunotoxicities resulting from Ipilimumab treatment can 
range from relatively minor conditions, such as skin depigmentation, to severe toxicities 
against crucial organ systems, such as liver, heart and lung. In the Ipilimumab registration 
trial Grade 3 or 4 IRAEs occurred in 10 to 15% of patients treated and seven deaths were 
associated with IRAEs (Hodi et al, 2010). Treatment-related toxicity correlates with better 
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responses in some cases, and it is likely that serious adverse events from immune-mediated 
reactions will increase in frequency and severity as immunotherapeutic approaches become 
more effective (Amost et al, 2011). Hence, scientists and physicians should be on guard for 
SAEs associated with augmented immune responses and strategies will have to be 
developed to avoid or circumvent these side effects. 
The use of viral vectors in past gene-therapy trials has been shown to cause the occurrence 
of leukemogenesis (Dunbar, 2007). This phenomenon has been linked to the use of retroviral 
vectors and is due to their integration into the host genome and the activation of adjacent 
proto-oncogenes. It is, therefore, important to carefully analyze whether genetic vaccines 
that make use of either naked DNA or viral vectors may raise similar issues. It has to be 
pointed out, however, that genetic vaccines bear two significant differences when compared 
to gene therapy with retroviral vectors. In first instance DNA, also following electroporation 
(Wang et al, 2004), as well as Adenoviral (Jager and Ehrhardt, 2007)  or Pox vectors used for 
cancer vaccines have a very low or null chromosomal  integration respectively in the host 
genome. The second aspect is that vaccines are inoculated at peripheral sites in the body 
such as dermal tissue or skeletal muscles which are mainly composed of terminally 
differentiated and mitotic quiescent cells. At any rate, Regulatory Agencies require the 
inclusion of genome integration and genotox studies for any new genetic vaccine as part of 
the documentation to be included in IND filings. 
5. Clinical endpoints 
Cancer Vaccines and Cancer Immunotherapy in general act via a gradual build up of immune 
responses in the body that eventually are expected to affect cancer growth and propagation. 
The realization that the kinetics of this process are relatively slow as compared to the more 
immediate effects of chemotherapy have led to the conclusion that the conventional clinical 
trial endpoints cannot be applied as such also to Cancer Immunotherapy trials, and that there 
was a need for the establishment of new and specific criteria. Several initiatives in this 
direction were started over the past years and were coordinated by the Cancer 
Immunotherapy Consortium of the Cancer Research Institute (CIC-CRI) in collaboration with 
the International Society for Biological Therapy of Cancer in USA and with the Association for 
Cancer Immunotherapy (C-IMT) in Europe. They led to the issuance in year 2009 of a guidance 
document by FDA (see next paragraph)whose principles are summarized below (for a detailed 
description, please refer to Hoos et al, 2010). 
Essentially three novel endpoint considerations, which require extensive validation by 
prospective assessment in clinical studies, were formulated: 1) Harmonize assays directed to 
assess cellular immune response to tumour antigens in order to minimize assay variability 
among clinical sites. The goal is to obtain a reproducible biomarker that eventually will 
allow to establish more precise correlations between immune response and clinical efficacy; 
2) Adopt new criteria for antitumour response which are adapted from the standard 
Response Evaluation Criteria in Solid Tumours (RECIST) criteria; 3) Use different statistical 
methods for trial design and assessment of survival outcomes. 
The Cancer Vaccine Clinical Trial Working group first proposed that immunoassays should 
be performed at least at three different time points, one baseline and two follow up. At least 
two assays should be used in parallel to provide relevant data to inform go/nogo decision 
for further development. Furthermore, the cutoff values for an immune response should be 
established prospectively both to define a positive vs negative response and to define the 
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proportion of patients needed to conclude for a positive outcome. With respect to assay 
harmonization it was soon realized that several assays are being used (ELISPOT, IFN- 
intracellular staining, HLA-peptide multimer-staining, etc) with principles and procedures 
different in different laboratories. This hampers data reproducibility and comparisons 
among studies. Immunomonitoring proficiency panels were launched to address these 
issues for individual assays. These panels have worked by accrual of patients’ samples  and 
preparation of peripheral blood mononuclear cells, which were then shipped and tested 
across multiple laboratories, using their respective protocols. Results were then centrally 
analyzed. The ELISPOT panel has been the longest running panel, and its results have led to 
initial ELISPOT harmonization guidelines (Janetzki et al, 2007), which are directed to 
address key variables across different laboratories that influence assay outcome, but do not 
impose assay standardizations (Hoos et al, 2010). 
Investigators rely on RECIST criteria to assess clinical activity of anticancer agents 
(Eisenhauer et al, 2009). These criteria nicely capture the effects of chemotherapeutic agents 
and measure tumour shrinkage. These criteria are used to distinguish Progressive Disease 
(PD) vs Stable Disease (SD), Partial Response (PR) or Complete Response (CR) and inform 
about trial continuation or discontinuation of experimental new therapies. However, it has 
become evident with time that RECIST criteria do not offer a complete description of the 
response to immunotherapeutic agents and need to be adjusted. This is due to the fact that 
the dynamics of antitumour effects of immunotherapeutic agents are in general much 
slower then chemotherapies and that in some cases patients with a stable disease, or a 
progressive disease at early time points, experience tumour regression at a later time. The 
Cancer Vaccine Clinical Trial Working Group addressed this issue, concluded that the 
appearance of measurable clinical activity for immunotherapies may take longer than for 
cytotoxic therapies (also after conventional progressive disease has been declared) and that 
application of standard RECIST criteria, may lead to inappropriate trial discontinuation 
(Hoos et al, 2007). By analyzing data from several different immunotherapy trials on a large 
number of patients a set of four distinct patterns were detected: immediate response, 
durable stable disease, response after tumour increase, and response in the presence of new 
lesions. While the first two patterns are included in conventional RECIST criteria, the other 
two are not. Therefore, in order to capture all patterns observed, the so called immune 
related Response Criteria (irRC) were formulated (Wolchok et al, 2009); irPD (immune-
related Progressive Disease), irSD (immune-related Stable Disease), irPR (immune-related 
Partial Response), irCR (immune-related Complete Response) using the same thresholds 
to distinguish between categories as in the standard RECIST criteria. However, there are 
two substantial differences: a) Progressive Disease is declared not simply upon the 
appearance of new tumour lesions but upon the measure of total tumour burden 
according to a precise formula (Hoos et al, 2010); b)  that measure should be confirmed at 
least at two consecutive time points. Using irRC the appearance of new tumour lesions 
alone does not constitute therefore irPD if they do not add to the total tumour burden 
measured at the initiation of the treatment by at least 25%, and if they are not confirmed 
at the subsequent time point. These new criteria are meaningful because they have 
received extensive validation in clinical trials with ipilimumab and have shown to 
correlate with favorable patients survival. However, their prospective evaluation in new 
trials is required to confirm their clinical utility. 
Finally, at variance with chemotherapy, where early clinical effects are possible, 
immunotherapies often show delayed clinical effects. This is evident when analyzing 
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Kaplan-Meier survival curves of Provenge trials (Kantoff et al, 2010), where delayed 
separation of survival curves between active treatment vs control is observed. If this delayed 
separation is a general phenomenon for immunotherapeutic agents, then the statistical 
power to differentiate the curves is reduced. Therefore new statistical paradigms need to be 
established which take this into account in order to avoid miscalculations in the number of 
patients to be accrued in Phase III registration trials, and in the number of events required to 
calculate Hazard Ratio and Confidence Interval. It is highly recommended in this case that 
the quantification to compute the required events comes from previous randomized well 
designed Phase II trials. 
In conclusion to this section we anticipate that the application of these new clinical 
endpoints is going to positively enhance the probability of success of cancer vaccines,  
allow faster and more informed GO/NOGO decisions in early clinical development and  
to prioritize agents that have the best profile to show statistically meaningful survival 
benefit. 
6. Regulatory perspectives 
Sipuleucel-T (Provenge®,Dendreon) is the only therapeutic cancer vaccine approved  
by FDA. However several promising vaccines such as M-Vax, (AVAX Technologies, Inc.) 
OncoVax (Vaccinogen), TroVax (Oxford Biomedica), ASCI MAGE-A3 (GSK), Oncophage® 
(Agenus) are in late stage development and are preparing for regulatory review in the 
United States, Europe, Canada, or other international regions (www.MarketResearch.com). 
Many of the products with potential approval status over the coming years are already  
in Phase III development, have orphan drug status, SPA status, or Fast Track status. As  
a signal of a new open attitude towards cancer vaccines, the FDA has recently issued  
new draft clinical trial guidelines for makers of therapeutic cancer vaccines intended to  
treat patients with existing disease (http://www.fda.gov/BiologicsBlood Vaccines 
/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm182443.htm). Most 
notably, the draft guidance, in line with the new criteria described in section 5. advises that 
time-to-tumor-progression may not be an appropriate endpoint for cancer vaccines and that 
immune response launched against the tumour may take longer than the time it takes for it 
to progress. As the mechanism of action for most cancer vaccines is thought to be mediated 
through amplifying a native T-cell response, especially cytotoxic T cells, regulators 
explained that development of a cancer vaccine can present different considerations for 
clinical trial design than development of a traditional cytotoxic drug or biological product 
for the treatment of cancer. Consequently, developers of cancer vaccines are now 
encouraged to move forward with new products, although they need to weigh the 
advantages and disadvantages of testing their agents in patients with metastatic diseases vs. 
patients with no evidence of residual disease or minimal burden of disease. 
7. Future directions  
We believe that therapeutic cancer vaccines have a bright future and that within the next ten 
years they will become an established therapeutic modality for cancer, in a manner similar 
to what have now become monoclonal antibodies. This success will strictly depend upon the 
respect of the four major principles listed below (see also Fig 2);  
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The “Key” to successful cancer 
vaccine development
Combinations 
with
chemotherapy
and/or
immunomodulators
Prime-boost
vaccination
technology against
whole tumor-antigen
(genetic vaccines)
Biomarker
strategy
Clinical development
inspired to
immune related
response criteria
 
Fig. 2. Components and requirements for successful cancer vaccines development. 
1. Use of a well established vaccination technology capable of inducing strong multi-
epitope antigen-specific T and B cell responses, while using reproducible and easily 
scalable technologies. In this respect we believe that the most promising platforms for 
vaccination are those based on the use of genetic vectors, primarily when used in 
heterologous prime-boost combinations; 
2. Appropriate combinations of vaccines with chemotherapy and/or with 
immunomodulators; 
3. Development of an articulated biomarker strategy, which allows in parallel with clinical 
development to reproducibly quantify antigen-specific T cell responses as a 
pharmacodynamic measure of vaccine immunogenicity, and to pre-select the best 
responders to treatment; 
4. A development paradigm that takes into account the evolving scenario and that is 
constantly inspired to the improved endpoints for cancer immunotherapy trials 
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